TherapeuticsMD, Inc. — Director's Dealing 2014

Feb 21, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2014-02-19

Reporting Person: Finizio Robert G (Director, CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-02-19	Common Stock	S	16700	$6.1681	Disposed	22044886	Direct
2014-02-20	Common Stock	S	16700	$6.173	Disposed	22028186	Direct
2014-02-21	Common Stock	S	16600	$6.1801	Disposed	22011586	Direct

Footnotes

F1: The shares were sold pursuant to a 10b5-1 Sales Plan dated December 9, 2013.

F2: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.35, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $6.04 to $6.25, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $6.11 to $6.33, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.